BioSpace News Archive

EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, reports the first patient in the Phase II ACESO trial has been dosed.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first-line gastroesophageal adenocarcinoma pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers.

Diverse Biotech, Inc. announced that its DBT-12733 molecule was more effective in killing glioblastoma tumor cells than temozolomide, outperforming all expectations in early testing.

Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day

SciNeuro Pharmaceuticals and Mabylon AG today announced the establishment of a multi-program collaboration and license agreement.

Catamaran Bio, Inc. today announced the formation of its scientific advisory board (SAB).

ContraFect Corporation today announces it will be presenting a poster on the activity of DLAs against common Gram-negative pathogens responsible for pulmonary infections in Cystic Fibrosis patients at the North American Cystic Fibrosis Conference, which will be held virtually from November 2-5, 2021.

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2 , 2021.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has been named by the Orange County Business Journal as the fastest growing publicly traded company in Orange County.